The more I read about theranos the more apparent it is that there is something fundamentally wrong with it's core goals, leadership and technology. One easily identifiable red flag is the composition of its board. It's nearly all ex-military and government officials not veteran entrepreneurs and technologists. Just to name a few: George Shultz (former Secretary of State), Sam Nunn and Bill Frist (former U.S. Senators), James Mattis (General, USMC, retired) and Gary Roughead (Admiral, USN, retired) Henry Kissinger (former Secretary of State), William Perry (former Secretary of Defense)
In discussion on other HN threads, some commenters suggested that the board was composed that way to grease the wheels of a DoD acquisition of the company's "tech". As OP put it [https://news.ycombinator.com/item?id=11403165]:
John the more I think about Theranos the more I think this “mess” is actually deliberate. Looking at the history of Theranos and the composition of the board it appears Theranos was designed from early on as a vehicle to defrauded the US military.
The plan appeared to be to use their connection and access to some rather “helpful” high brass to offload the technology for billions and then later sweep the fact that it didn’t work under the rug (this tactic has worked fabulously for the last 20 years). Avoid the FDA altogether.
Who would have noticed another $10 billion misspent on some wizz-bang technology given the $100s billions lost in other frauds? When the wheels fell of this plan (some underling didn’t play along) the idea seems to be to blame the scientists and say “we were misled”. They might be evil, but they don’t appear to be stupid.
The first part seems probable (sell to the DoD), but intentional fraud is unlikely. Remember Hanlon's Razor - "Never ascribe to malice that which can be explained by incompetence."
It seems more likely they were very close on the science, and decided to run with it while they worked out the last 10%. That works great for most tech companies, but healthcare technology is very different.
That's my read on it - the board members probably all know each other, or are friends-of-friends. Just like you and I, corporate board members recommend their friends when positions are open.
It probably doesn't hurt to have people like that on your board when you go looking for funding.
Being on a corporate board has got to be the easiest job in the world. When things are going well you collect a six or seven figure paycheck for doing almost nothing.
No. In fact all the independent data suggests that it is impossible with less than 4 drops of blood (~100µl) due to sampling issues. No matter how great the detection technology is if you are not able to get a representative sample then the end result will be garbage.
If 4 drops is a low bound, couldn't they have aimed for say 10? Can't you draw 10 drops of blood relatively easily from the finger? I feel like I've had that done before when donating blood. It'd still be a much less annoying process than vials after vials like it seems like most blood testing is.
It's hard for me to imagine they wouldn't have said "well, one drop didn't work but we could decently with four but we won't do that."
It is really hard to get more than a single drop out of fingerprick. The reason why is the capillaries close up very quickly - if you are really lucky you can get 2 drops out, but anything more is a struggle.
The second problem with fingerprick blood is you pick up quite a bit of skin tissue in the process, but the amount collected is quite variable. What you end up measuring is blood + some unknown percentage of skin tissue derived material. None of these things are good for reproducibility.
More like they had a taste of the science and decided to work out the last 90%..
But that's actually the right way to do science generally.... Just not in this case.
Yup, when I make a mistake in my income tax filing and over pay by $2k that's incompetence. I wouldn't be so sure about attributing an unreported offshore shell company holding millions of dollars as incompetence.
I'm a little confused, does the military acquire companies wholesale? I've never heard of that happening, that's not to say it can't but what are some examples of this kind of scheme?
Instead was the plan to milk the military for a long time on R&D expenses and just pocket the cash as one goes along? If so how does that work for the VC-backed structure of the company?
I can answer that for you. No, the US military does not acquire private companies, except in extraordinary circumstances of national security (think: WW2 type events). They'd only do it if the company possesses something of extreme strategic importance and could no longer operate as an on-going concern, and the first thing they'd do is try to arrange a sale to another friendly defense contractor. Buying a private company would be the very last thing they would do in the chain of actions there; further, what they would do, is purchase the technology, not the corporation.
Accordingly, the theory about Theranos being set-up to be sold to the DoD, falls entirely flat.
I have no expertise in any of this, but I was assuming it would be something along the lines of an IDIQ (indefinite delivery, indefinite quantity) contract vehicle: https://en.wikipedia.org/wiki/IDIQ
That makes some sense, though it seems they'd have to deliver something in that case. I'm sure one could keep the charade going for a little bit by delaying/delivering stuff that didn't work, but eventually the docs in the army medical corp would start to raise red flags and the jig would be up. One hopes anyway?
>The plan appeared to be to use their connection and access to some rather “helpful” high brass to offload the technology for billions and then later sweep the fact that it didn’t work under the rug (this tactic has worked fabulously for the last 20 years). Avoid the FDA altogether.
IMO The Theranos basic concept is viable, but their implementation is flawed.
There have been somewhat recent cases of the SECDEF firing a General or Admiral if a development or acquisition goes awry. The JSF Program Executive Officer, MG David Heinz [0] was one example. I doubt a senior officer would risk a $10Bn acquisition program on unverified technology. Development programs are another story.
The Defense Contract Management Agency (DCMA) [1] are known for being rigid when it comes to the units meeting contracted specifications. They also require technical documentation, so trade secret wouldn't be an excuse. If DCMA are on vacation, then no deliveries take place. This happened during federal shutdowns.
If Theranos sold the DoD a device that was faked and didn't meet specifications, It's entirely likely DCMA would reject the delivery.
Development programs with DoD funding sometimes (often?) go awry, and sometimes specifications get changed (e.g F-35) but the unit must meet contractual specifications.
There is a market for low cost, minimally invasive lab tests.
Using a smaller needle can be done. A skilled doctor or nurse can use a butterfly needle [0] with a fine tip, and the patient barely notices. As I recall, a 27G needle is about the smallest and not damage the blood cells.
Microfluidic Arrays [1] are one way to carry out some lab tests with smaller samples. What steps are required to get the results from the array would vary between tests.
YC (W16) funded Unima [2] is working on reducing the cost of certain lab tests with paper test strips.
The plan appeared to be to use their connection and access to some rather “helpful” high brass to offload the technology for billions and then later sweep the fact that it didn’t work under the rug (this tactic has worked fabulously for the last 20 years). Avoid the FDA altogether.
While I'm sure this has happened in weapons technology, can you give an example in Health Care? (Where people deliberately avoided the FDA this way) I know there's a ton of waste in the military, I wasn't aware it spread this wide and deep.
The company didn't start as a way to draw blood for civilians but for a quicker/easier way to draw blood on the battle field...hence the original board composition.
That's not strictly true, the board composition was far more traditional prior to 2013, a lot of these government guys came on at that point. From the wikipedia article:
In July 2013, the composition of the Theranos board of directors changed markedly, with departure of Channing Robertson (emeritus professor, chemical engineering, Stanford University),[39] experienced pharma and biotech executive Robert B. Shapiro (former chairman/CEO of the Pharmacia, Monsanto, and G.D. Searle group of companies), and financier Pete Thomas (principal, ATA Ventures).[6][38] Remaining from the original board were Theranos President and COO Ramesh "Sunny" Balwani and former Secretary of State George Shultz;
I think you need to read what the military have to say on this topic [1].
It is estimated that six percent of all procurement dollars are lost to fraud nation-wide annually. If you apply that amount to USAspending.gov’s figure of $700 billion dollars that the Federal Government spent on average each of the past nine years, that would total $42 billion dollars per year or $378 billion dollars lost to procurement fraud during the past nine years.
Medicare fraud is something like $60 billion or 10% of total spending. It's conceivable that the rest of the government would approach some multiple of $100 billion, even having lower rates of fraud than Medicare.
I have met many later-in-their-career, senior government folks cultivating a transition into the private sector.
They seem particularly vulnerable to this kind of catastrophe. It's like they have their favored peers who are also retiring & they get them connected to a firm by someone who also left and wants to help out other govies. They do 20 years in the military and then go work in private sector for companies that will sell to the government. So the board gets loaded up with civil servants rather than entrepreneurs.
My perception is that their career experience doesn't arm them with the ability to identify a company with inadequate runway & execution talent. They seem to think a a well connected "who-you-know" network would have enough collective wisdom to avoid this scenario, or maybe they don't really consider that failure is possible, given the funding environment of the military.
Umm, the good doctor's wealth comes from HCA, a chain of for-profit hospitals that once held the record for the largest fraud settlement in US history. Frist clearly has excellent PR, because very few people ever mention this.
Frist makes sense on the board in that he definitely knows who to call at the FDA and would get his call answered. As unsavory as it is, lobbying experience is valuable in tightly regulated industries. I have no idea if he's a good doc, or the ethics of HCA, but from a purely pragmatic perspective, of all the names his makes the most sense on that board.
What if the company had been wildly successful, would you still view it's board composition in the same light? I agree with you, these are some pretty powerful 'non-scientific' people and it should raise some questions.
What kind of questions exactly? It seems to me that having such powerful, influential, former members of government on your board would be highly valuable in navigating the difficult regulatory environment companies in this industry face.
Why do you have Henry Kissinger on your board and not a veteran medical device or medical test industry expert. Henry Kissinger might have tons of foreign policy experience but this is a completely different field.
If you could get Henry Kissinger on your board and don't have moral issues with him, why wouldn't you? I absolutely understand where you are coming from, but in that respect Kissinger is definitively an exception, because while he may not have the medical credentials, he has tremendous value just because he is someone who is so well known that he can be a door-opener "anywhere".
He's also run a consulting company that's specialising in identifying partners and acting as door-opener for the last 34 years.
In other words: He's not on that board for his expertise in their field, but for his expertise and contacts related to getting in to talk to the right people.
It is undoubtedly helpful to have people on your board who understand the regulatory mechanisms and industry (leaving aside how well the Theranos board actually does this)
Composition of a board is tricky though. In a case like this you would hope to have equal, if not dominant, representation of people who are strong on the science. Anything else is a bit of a red flag.
Yeah, the board members all fit into "ideas guy" archetype. AKA a useless moron that doesn't contribute to the end product in any way, but still takes all the credit for it.
Sailor makes the case that there's a strong dose of affirmative action involved. His blog posts don't really contribute much to the discussion other than adding that slight "politically incorrect" slant. His posts just pull from all the other sources people have already mentioned.
I don't agree with your characterization of the main post, you may also consider that for someone interested in this matter, there is additional information in the comment sections of the linked posts.
I'm also perplexed as to the driving factor behind your somewhat dickish, snide comment.
https://en.wikipedia.org/wiki/Theranos#Governance